Jorge Cortes

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Physiology

Neoplasm Drug Resistance

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Quintás-Cardama Alfonso; Kantarjian Hagop; Manshouri Taghi; Luthra Rajyalakshmi; Estrov Zeev; Pierce Sherry; Richie Mary Ann; Borthakur Gautam; Konopleva Marina; Cortes Jorge; Verstovsek Srdan
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
Quintás-Cardama Alfonso; Kantarjian Hagop M; Manshouri Taghi; Thomas Deborah; Cortes Jorge; Ravandi Farhad; Garcia-Manero Guillermo; Ferrajoli Alessandra; Bueso-Ramos Carlos; Verstovsek Srdan
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Mak Duncan H; Schober Wendy D; Chen Wenjing; Konopleva Marina; Cortes Jorge; Kantarjian Hagop M; Andreeff Michael; Carter Bing Z
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Jorge Cortes (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Quintás-Cardama Alfonso; Kantarjian Hagop; Manshouri Taghi; Luthra Rajyalakshmi; Estrov Zeev; Pierce Sherry; Richie Mary Ann; Borthakur Gautam; Konopleva Marina; Cortes Jorge; Verstovsek Srdan
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(32):5418-24.
2009: Quintás-Cardama Alfonso; Kantarjian Hagop M; Manshouri Taghi; Thomas Deborah; Cortes Jorge; Ravandi Farhad; Garcia-Manero Guillermo; Ferrajoli Alessandra; Bueso-Ramos Carlos; Verstovsek Srdan
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4760-6.
2009: Mak Duncan H; Schober Wendy D; Chen Wenjing; Konopleva Marina; Cortes Jorge; Kantarjian Hagop M; Andreeff Michael; Carter Bing Z
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
Molecular cancer therapeutics 2009;8(9):2509-16.
2009: Quintás-Cardama Alfonso; Cortes Jorge
Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?
Current oncology reports 2009;11(5):337-45.
2009: Quintás-Cardama Alfonso; Kantarjian Hagop; Cortes Jorge
Imatinib and beyond--exploring the full potential of targeted therapy for CML.
Nature reviews. Clinical oncology 2009;6(9):535-43.
2009: Jabbour Elias; Jones Daniel; Kantarjian Hagop M; O'Brien Susan; Tam Constantine; Koller Charles; Burger Jan A; Borthakur Gautam; Wierda William G; Cortes Jorge
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
Blood 2009;114(10):2037-43.
2009: Kantarjian Hagop; Pasquini Ricardo; Lévy Vincent; Jootar Saengsuree; Holowiecki Jerzy; Hamerschlak Nelson; Hughes Timothy; Bleickardt Eric; Dejardin David; Cortes Jorge; Shah Neil P
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
Cancer 2009;115(18):4136-47.
2009: Jain Nitin; Reuben James M; Kantarjian Hagop; Li Changping; Gao Hui; Lee Bang-Ning; Cohen Evan N; Ebarb Theresa; Scheinberg David A; Cortes Jorge
Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial.
Cancer 2009;115(17):3924-34.
2009: Verma Dushyant; Kantarjian Hagop M; Jones Dan; Luthra Rajyalakshmi; Borthakur Gautam; Verstovsek Srdan; Rios Mary Beth; Cortes Jorge
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Blood 2009;114(11):2232-5.
2009: Quintás-Cardama Alfonso; De Souza Santos Fabio Pires; Kantarjian Hagop; O'Brien Susan; Faderl Stefan; Awais Ahmed; Borthakur Gautam; Cortes Jorge
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.
Cancer 2009;115(17):3935-43.
2009: Alvarado Yesid; Kantarjian Hagop; O'Brien Susan; Faderl Stefan; Borthakur Gautam; Burger Jan; Wierda William; Garcia-Manero Guillermo; Shan Jianqin; Cortes Jorge
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.
Cancer 2009;115(16):3709-18.
2009: Kantarjian Hagop M; Shan Jianqin; Jones Daniel; O'Brien Susan; Rios Mary Beth; Jabbour Elias; Cortes Jorge
Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(22):3659-63.
2009: Nussenzveig Roberto H; Cortes Jorge; Sever Matjaz; Quintás-Cardama Alfonso; Ault Pat; Manshouri Taghi; Bueso-Ramos Carlos; Prchal Josef T; Kantarjian Hagop; Verstovsek Srdan
Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001.
International journal of hematology 2009;90(1):58-63.
2009: Garg R; Faderl S; Garcia-Manero G; Cortes J; Koller C; Huang X; York S; Pierce S; Brandt M; Beran M; Borthakur G; Kantarjian H; Ravandi F
Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(7):1297-302.
2009: Ma Wanlong; Kantarjian Hagop; Bekele Benjamin; Donahue Amber C; Zhang Xi; Zhang Zhong J; O'Brien Susan; Estey Elihu; Estrov Zeev; Cortes Jorge; Keating Michael; Giles Francis; Albitar Maher
Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(11):3820-6.
2009: Kantarjian Hagop; Cortes Jorge; Kim Dong-Wook; Dorlhiac-Llacer Pedro; Pasquini Ricardo; DiPersio John; Müller Martin C; Radich Jerald P; Khoury H Jean; Khoroshko Nina; Bradley-Garelik M Brigid; Zhu Chao; Tallman Martin S
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
Blood 2009;113(25):6322-9.
2009: Quintás-Cardama Alfonso; Kantarjian Hagop; Ravandi Farhad; O'Brien Susan; Thomas Deborah; Vidal-Senmache Gabriela; Wierda William; Kornblau Steven; Cortes Jorge
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.
Cancer 2009;115(11):2482-90.
2009: Jain Nitin; Cortes Jorge; Quintás-Cardama Alfonso; Manshouri Taghi; Luthra Raja; Garcia-Manero Guillermo; Kantarjian Hagop; Verstovsek Srdan
Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.
Leukemia research 2009;33(6):837-9.
2009: Vega-Ruiz Arturo; Faderl Stefan; Estrov Zeev; Pierce Sherry; Cortes Jorge; Kantarjian Hagop; Ravandi Farhad
Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience.
International journal of hematology 2009;89(4):489-96.
2009: Fava Carmen; Kantarjian Hagop M; Jabbour Elias; O'Brien Susan; Jain Nitin; Rios Mary Beth; Garcia-Manero Guillermo; Ravandi Farhad; Verstovsek Srdan; Borthakur Gautam; Shan Jianqin; Cortes Jorge
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
Blood 2009;113(21):5058-63.
2009: Fava Carmen; Cortes Jorge
Optimizing first-line therapy for patients with chronic myeloid leukemia.
Seminars in hematology 2009;46(2 Suppl 3):S5-10.
2009: Verma Dushyant; Fava Carmen; Kantarjian Hagop; Cortes Jorge
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.
American journal of hematology 2009;84(4):256-7.
2009: Wierda William G; O'Brien Susan; Wang Xuemei; Faderl Stefan; Ferrajoli Alessandra; Do Kim-Anh; Garcia-Manero Guillermo; Cortes Jorge; Thomas Deborah; Koller Charles; Burger Jan; Lerner Susan; Kantarjian Hagop; Keating Michael
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(10):1637-43.
2009: Tam Constantine S; Abruzzo Lynne V; Lin Katherine I; Cortes Jorge; Lynn Alice; Keating Michael J; Thomas Deborah A; Pierce Sherry; Kantarjian Hagop; Verstovsek Srdan
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.
Blood 2009;113(18):4171-8.
2009: Cortes Jorge; De Keersmaecker Kim
T-Cell acute lymphoblastic leukemia with a "pinch" of BCR-ABL1.
Leukemia & lymphoma 2009;50(3):321-2.
2009: Kantarjian Hagop M; Larson Richard A; Guilhot Francois; O'Brien Stephen G; Mone Manisha; Rudoltz Marc; Krahnke Tillmann; Cortes Jorge; Druker Brian J;
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.
Cancer 2009;115(3):551-60.
2009: Ravandi Farhad; Estey Eli; Jones Dan; Faderl Stefan; O'Brien Susan; Fiorentino Jackie; Pierce Sherry; Blamble Deborah; Estrov Zeev; Wierda William; Ferrajoli Alessandra; Verstovsek Srdan; Garcia-Manero Guillermo; Cortes Jorge; Kantarjian Hagop
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(4):504-10.
2009: Quintás-Cardama Alfonso; Cortes Jorge
Molecular biology of bcr-abl1-positive chronic myeloid leukemia.
Blood 2009;113(8):1619-30.
2009: Jabbour Elias; Cortes Jorge; Kantarjian Hagop
Treatment selection after imatinib resistance in chronic myeloid leukemia.
Targeted oncology 2009;4(1):3-10.
2009: Verma Dushyant; O'Brien Susan; Thomas Deborah; Faderl Stefan; Koller Charles; Pierce Sherry; Kebriaei Partow; Garcia-Manero Guillermo; Cortes Jorge; Kantarjian Hagop; Ravandi Farhad
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
Cancer 2009;115(1):101-6.
2009: Ault Patricia; Cortes Jorge; Lynn Alice; Keating Michael; Verstovsek Srdan
Pregnancy in a patient with hypereosinophilic syndrome.
Leukemia research 2009;33(1):186-7.
2008: O'Brien Susan; Thomas Deborah; Ravandi Farhad; Faderl Stefan; Cortes Jorge; Borthakur Gautum; Pierce Sherry; Garcia-Manero Guillermo; Kantarjian Hagop M
Outcome of adults with acute lymphocytic leukemia after second salvage therapy.
Cancer 2008;113(11):3186-91.
2008: Kantarjian Hagop; O'Brien Susan; Cortes Jorge; Wierda William; Faderl Stefan; Garcia-Manero Guillermo; Issa Jean-Pierre; Estey Elihu; Keating Michael; Freireich Emil J
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.
Cancer 2008;113(7 Suppl):1933-52.
2008: Aribi Ahmed; Kantarjian Hagop; Koller Charles; Thomas Deborah; Faderl Stefan; Garcia-Manero Guillermo; Cortes Jorge
The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Cancer 2008;113(6):1338-43.
2008: Kantarjian Hagop; O'Brien Susan; Ravandi Farhad; Cortes Jorge; Shan Jianqin; Bennett John M; List Alan; Fenaux Pierre; Sanz Guillermo; Issa Jean-Pierre; Freireich Emil J; Garcia-Manero Guillermo
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.
Cancer 2008;113(6):1351-61.
2008: Vega-Ruiz Arturo; O'Brien Susan; Cortes Jorge; Kebriaei Partow; Thomas Deborah; Kantarjian Hagop; Ravandi Farhad
Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.
Leukemia research 2008;32(9):1468-71.
2008: Garcia-Manero Guillermo; Assouline Sarit; Cortes Jorge; Estrov Zeev; Kantarjian Hagop; Yang Hui; Newsome Willie M; Miller Wilson H; Rousseau Caroline; Kalita Ann; Bonfils Claire; Dubay Marja; Patterson Tracy-Ann; Li Zuomei; Besterman Jeffrey M; Reid Gregory; Laille Eric; Martell Robert E; Minden Mark
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.
Blood 2008;112(4):981-9.
2008: Tam Constantine S; Kantarjian Hagop; Garcia-Manero Guillermo; Borthakur Gautam; O'Brien Susan; Ravandi Farhad; Shan Jenny; Cortes Jorge
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.
Blood 2008;112(3):516-8.
2008: Tam Constantine S; O'Brien Susan; Wierda William; Kantarjian Hagop; Wen Sijin; Do Kim-Anh; Thomas Deborah A; Cortes Jorge; Lerner Susan; Keating Michael J
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
Blood 2008;112(4):975-80.
2008: Quintás-Cardama Alfonso; Cortes Jorge
Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones.
Leukemia research 2008;32(8):1313-6.
2008: Quintás-Cardama Alfonso; Cortes Jorge
Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4392-9.
2008: Jabbour Elias; El Ahdab Samih; Cortes Jorge; Kantarjian Hagop
Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias.
Expert opinion on investigational drugs 2008;17(7):1127-36.
2008: Quintás-Cardama Alfonso; Cortes Jorge
Therapeutic options for patients with clonal and idiopathic hypereosinophia.
Expert opinion on investigational drugs 2008;17(7):1039-50.
2008: Borthakur Gautam; Alvarado Yesid; Ravandi-Kashani Farhad; Cortes Jorge; Estrov Zeev; Faderl Stefan; Ivy Percy; Bueso-Ramos Carlos; Nebiyou Bekele B; Giles Francis
Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies.
Cancer 2008;113(2):360-6.
2008: Jabbour Elias; Kantarjian Hagop; Jones Dan; Breeden Megan; Garcia-Manero Guillermo; O'Brien Susan; Ravandi Farhad; Borthakur Gautam; Cortes Jorge
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.
Blood 2008;112(1):53-5.
2008: Verstovsek Srdan; Tefferi Ayalew; Cortes Jorge; O'Brien Susan; Garcia-Manero Guillermo; Pardanani Animesh; Akin Cem; Faderl Stefan; Manshouri Taghi; Thomas Deborah; Kantarjian Hagop
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(12):3906-15.
2008: Quintás-Cardama A; Tong W; Manshouri T; Vega F; Lennon P A; Cools J; Gilliland D G; Lee F; Cortes J; Kantarjian H; Garcia-Manero G
Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(6):1117-24.
2008: Jilani Iman; Kantarjian Hagop; Faraji Homan; Gorre Mercedes; Cortes Jorge; Ottmann Oliver; Bhalla Kapil; O'Brien Susan; Giles Francis; Albitar Maher
An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation.
Leukemia research 2008;32(6):936-43.
2008: Quintás-Cardama Alfonso; Cortes Jorge
Management of patients with resistant or refractory chronic myelogenous leukemia.
Oncology (Williston Park, N.Y.) 2008;22(4):430-7; discussion 437, 442, 446 passim.
2008: Awais Ahmed; Tam Constantine S; Kontoyiannis Dimitrios; Ferrajoli Alessandra; Duvic Madeleine; Cortes Jorge; Keating Michael J
Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;46(7):e69-71.
2008: Quintás-Cardama Alfonso; Cortes Jorge
Homoharringtonine for the treatment of chronic myelogenous leukemia.
Expert opinion on pharmacotherapy 2008;9(6):1029-37.
2008: Zhang W; Konopleva M; Ruvolo V R; McQueen T; Evans R L; Bornmann W G; McCubrey J; Cortes J; Andreeff M
Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(4):808-18.
2008: Jilani Iman; Kantarjian Hagop; Gorre Mercedes; Cortes Jorge; Ottmann Oliver; Bhalla Kapil; Giles Francis J; Albitar Maher
Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Leukemia research 2008;32(4):643-9.
2008: Kantarjian Hagop; Cortes Jorge
BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
Journal of the National Comprehensive Cancer Network : JNCCN 2008;6 Suppl 2():S37-42; quiz S43-S44.
2008: Cortes Jorge; Kantarjian Hagop
Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN 2008;6 Suppl 2():S22-S30.
2008: Garcia-Manero G; Shan J; Faderl S; Cortes J; Ravandi F; Borthakur G; Wierda W G; Pierce S; Estey E; Liu J; Huang X; Kantarjian H
A prognostic score for patients with lower risk myelodysplastic syndrome.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(3):538-43.
2008: Verstovsek Srdan; Manshouri Taghi; Quintás-Cardama Alfonso; Harris David; Cortes Jorge; Giles Francis J; Kantarjian Hagop; Priebe Waldemar; Estrov Zeev
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(3):788-96.
2008: Tsimberidou Apostolia-Maria; Kantarjian Hagop M; Wen Sijin; O'Brien Susan; Cortes Jorge; Wierda William G; Koller Charles; Pierce Sherry; Brandt Mark; Freireich Emil J; Keating Michael J; Estey Elihu H
The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(3):721-30.
2008: Zhang Weiguo; Konopleva Marina; Shi Yue-xi; McQueen Teresa; Harris David; Ling Xiaoyang; Estrov Zeev; Quintás-Cardama Alfonso; Small Donald; Cortes Jorge; Andreeff Michael
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Journal of the National Cancer Institute 2008;100(3):184-98.
2008: Kantarjian Hagop; O'Brien Susan; Shan Jianqin; Huang Xuelin; Garcia-Manero Guillermo; Faderl Stefan; Ravandi-Kashani Farhad; Verstovsek Srdan; Beth Rios Mary; Cortes Jorge
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
Cancer 2008;112(4):837-45.
2008: Garcia-Manero Guillermo; Yang Hui; Bueso-Ramos Carlos; Ferrajoli Alessandra; Cortes Jorge; Wierda William G; Faderl Stefan; Koller Charles; Morris Gail; Rosner Gary; Loboda Andrey; Fantin Valeria R; Randolph Sophia S; Hardwick James S; Reilly John F; Chen Cong; Ricker Justin L; Secrist J Paul; Richon Victoria M; Frankel Stanley R; Kantarjian Hagop M
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Blood 2008;111(3):1060-6.
2007: Cortes Jorge; Jabbour Elias; Kantarjian Hagop; Yin C Cameron; Shan Jianqin; O'Brien Susan; Garcia-Manero Guillermo; Giles Francis; Breeden Megan; Reeves Nubia; Wierda William G; Jones Dan
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.
Blood 2007;110(12):4005-11.
2007: Jabbour Elias; Cortes Jorge; Giles Francis; Kantarjian Hagop
Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment.
Cancer journal (Sudbury, Mass.) 2007;13(6):357-65.
2007: Jabbour Elias; Kantarjian Hagop; Cortes Jorge; Thomas Deborah; Garcia-Manero Guillermo; Ferrajoli Alessandra; Faderl Stefan; Richie Mary Ann; Beran Miloslav; Giles Francis; Verstovsek Srdan
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
Cancer 2007;110(9):2012-8.
2007: Cortes Jorge; Quintás-Cardama Alfonso; Garcia-Manero Guillermo; O'Brien Susan; Jones Dan; Faderl Stefan; Ebarb Theresa; Giles Francis; Thomas Deborah; Kantarjian Hagop
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
Cancer 2007;110(9):2000-6.
2007: Atallah Ehab; Cortes Jorge; O'Brien Susan; Pierce Sherry; Rios Mary Beth; Estey Elihu; Markman Maurie; Keating Michael; Freireich Emil J; Kantarjian Hagop
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia.
Blood 2007;110(10):3547-51.
2007: Quintas-Cardama Alfonso; Cortes Jorge
Nilotinib therapy in chronic myelogenous leukemia.
Drugs of today (Barcelona, Spain : 1998) 2007;43(10):691-702.
2007: Quintás-Cardama Alfonso; Kantarjian Hagop; Cortes Jorge
Flying under the radar: the new wave of BCR-ABL inhibitors.
Nature reviews. Drug discovery 2007;6(10):834-48.
2007: Jabbour Elias; Kantarjian Hagop M; Abruzzo Lynne V; O'Brien Susan; Garcia-Manero Guillermo; Verstovsek Srdan; Shan Jianqin; Rios Mary Beth; Cortes Jorge
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Blood 2007;110(8):2991-5.
2007: Soriano Andres O; Yang Hui; Faderl Stefan; Estrov Zeev; Giles Francis; Ravandi Farhad; Cortes Jorge; Wierda William G; Ouzounian Souzanne; Quezada Andres; Pierce Sherry; Estey Elihu H; Issa Jean-Pierre J; Kantarjian Hagop M; Garcia-Manero Guillermo
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Blood 2007;110(7):2302-8.
2007: Quintás-Cardama Alfonso; Kantarjian Hagop; O'brien Susan; Borthakur Gautham; Bruzzi John; Munden Reginald; Cortes Jorge
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(25):3908-14.
2007: Cortes Jorge; Jabbour Elias; Daley George Q; O'Brien Susan; Verstovsek Srdan; Ferrajoli Alessandra; Koller Charles; Zhu Yali; Statkevich Paul; Kantarjian Hagop
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
Cancer 2007;110(6):1295-302.
2007: Kontoyiannis Dimitrios P; Chamilos Georgios; Lewis Russell E; Giralt Sergio; Cortes Jorge; Raad Issam I; Manning John T; Han Xin
Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation.
Cancer 2007;110(6):1303-6.
2007: Pan Jingxuan; Quintás-Cardama Alfonso; Manshouri Taghi; Cortes Jorge; Kantarjian Hagop; Verstovsek Srdan
Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406.
Cancer science 2007;98(8):1223-5.
2007: Ostronoff Fabiana; Bueso-Ramos Carlos; Cortes Jorge; Giralt Sergio
Normal hematopoietic function and multiple bone marrow clonal abnormalities in a patient with acute myeloid leukemia after two mismatched stem-cell transplants with graft failure and autologous reconstitution.
American journal of hematology 2007;82(8):744-7.
2007: Atallah Ehab; Durand Jean-Bernard; Kantarjian Hagop; Cortes Jorge
Congestive heart failure is a rare event in patients receiving imatinib therapy.
Blood 2007;110(4):1233-7.
2007: Jabbour Elias; Cortes Jorge; Giles Francis; O'Brien Susan; Kantarijan Hagop
Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
IDrugs : the investigational drugs journal 2007;10(7):468-79.
2007: Aribi Ahmed; Bueso-Ramos Carlos; Estey Eli; Estrov Zeev; O'Brien Susan; Giles Francis; Faderl Stefan; Thomas Deborah; Kebriaei Partow; Garcia-Manero Guillermo; Pierce Sherry; Cortes Jorge; Kantarjian Hagop; Ravandi Farhad
Biphenotypic acute leukaemia: a case series.
British journal of haematology 2007;138(2):213-6.
2007: Jabbour Elias; Cortes Jorge; Kantarjian Hagop; Giralt Sergio; Andersson Borje S; Giles Francis; Shpall Elizabeth; Kebriaei Partow; Champlin Richard; de Lima Marcos
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.
Cancer 2007;110(2):340-4.
2007: Pan J; Quintás-Cardama A; Manshouri T; Giles F J; Lamb P; Tefferi A; Cortes J; Kantarjian H; Verstovsek S
The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(7):1395-404.
2007: Beran Miloslav; Wen Sijin; Shen Yu; Onida Francesco; Jelinek Jaroslav; Cortes Jorge; Giles Francis; Kantarjian Hagop
Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System.
Leukemia & lymphoma 2007;48(6):1150-60.
2007: Wierda William G; O'Brien Susan; Wang Xuemei; Faderl Stefan; Ferrajoli Alessandra; Do Kim-Anh; Cortes Jorge; Thomas Deborah; Garcia-Manero Guillermo; Koller Charles; Beran Miloslav; Giles Francis; Ravandi Farhad; Lerner Susan; Kantarjian Hagop; Keating Michael
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.
Blood 2007;109(11):4679-85.
2007: Jabbour Elias; Cortes Jorge; Kantarjian Hagop
Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?
Oncology (Williston Park, N.Y.) 2007;21(6):653-62; discussion 663-4, 667-8.
2007: Jabbour Elias; Cortes Jorge; Kantarjian Hagop
Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
Expert opinion on investigational drugs 2007;16(5):679-87.
2007: Quintás-Cardama Alfonso; Cortes Jorge
Evaluation of the L-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia.
Expert opinion on investigational drugs 2007;16(4):547-57.
2007: Kantarjian Hagop; O'Brien Susan; Talpaz Moshe; Borthakur Gautam; Ravandi Farhad; Faderl Stefan; Verstovsek Srdan; Rios Mary Beth; Shan Jianqin; Giles Francis; Cortes Jorge
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
Cancer 2007;109(8):1556-60.
2007: Kantarjian Hagop M; Cortes Jorge; Guilhot Francçois; Hochhaus Andreas; Baccarani Michele; Lokey Lee
Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns.
Cancer 2007;109(7):1365-75.
2007: Cortes Jorge; Rousselot Philippe; Kim Dong-Wook; Ritchie Ellen; Hamerschlak Nelson; Coutre Steven; Hochhaus Andreas; Guilhot Francois; Saglio Giuseppe; Apperley Jane; Ottmann Oliver; Shah Neil; Erben Philipp; Branford Susan; Agarwal Prasheen; Gollerkeri Ashwin; Baccarani Michele
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
Blood 2007;109(8):3207-13.
2007: Kornblau Steven M; Banker Deborah E; Stirewalt Derek; Shen Danny; Lemker Elizabeth; Verstovsek Srdan; Estrov Zeev; Faderl Stefan; Cortes Jorge; Beran Miloslav; Jackson C Ellen; Chen Wenjing; Estey Elihu; Appelbaum Frederick R
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.
Blood 2007;109(7):2999-3006.
2007: Atallah Ehab; Kantarjian Hagop; Cortes Jorge
Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors.
Clinical lymphoma & myeloma 2007;7 Suppl 3():S105-12.
2007: Jabbour Elias; Cortes Jorge; O'Brien Susan; Rios Mary Beth; Giles Francis; Kantarjian Hagop
Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.
Clinical lymphoma & myeloma 2007;7 Suppl 2():S51-7.
2007: Kantarjian Hagop M; O'Brien Susan; Huang Xuelin; Garcia-Manero Guillermo; Ravandi Farhad; Cortes Jorge; Shan Jianqin; Davisson Jan; Bueso-Ramos Carlos E; Issa Jean-Pierre
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.
Cancer 2007;109(6):1133-7.
2007: Jabbour Elias; Kantarjian Hagop; Cortes Jorge
Clinical activity of tipifarnib in hematologic malignancies.
Expert opinion on investigational drugs 2007;16(3):381-92.
2007: Atallah Ehab; Cortes Jorge
Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Current opinion in hematology 2007;14(2):138-44.
2007: Oki Yasuhiro; Kantarjian Hagop M; Gharibyan Vazganush; Jones Dan; O'brien Susan; Verstovsek Srdan; Cortes Jorge; Morris Gail M; Garcia-Manero Guillermo; Issa Jean-Pierre J
Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.
Cancer 2007;109(5):899-906.
2007: Quintás-Cardama Alfonso; Kantarjian Hagop; Garcia-Manero Guillermo; O'Brien Susan; Faderl Stefan; Ravandi Farhad; Giles Francis; Thomas Deborah; Wierda William; Cortes Jorge
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
Leukemia & lymphoma 2007;48(2):283-9.
2007: Kantarjian Hagop M; Giles Francis; Quintás-Cardama Alfonso; Cortes Jorge
Important therapeutic targets in chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(4):1089-97.
2007: Giles Francis J; Borthakur Gautam; Ravandi Farhad; Faderl Stefan; Verstovsek Srdan; Thomas Deborah; Wierda William; Ferrajoli Alessandra; Kornblau Steven; Pierce Sherry; Albitar Maher; Cortes Jorge; Kantarjian Hagop
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
British journal of haematology 2007;136(4):624-7.
2007: Aribi Ahmed; Borthakur Gautam; Ravandi Farhad; Shan Jianqin; Davisson Jan; Cortes Jorge; Kantarjian Hagop
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
Cancer 2007;109(4):713-7.
2007: Jabbour Elias; Cortes Jorge; O'Brien Susan; Giles Francis; Kantarjian Hagop
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
Seminars in hematology 2007;44(1 Suppl 1):S25-31.
2007: Quintás-Cardama Alfonso; Kantarjian Hagop; Garcia-Manero Guillermo; O'Brien Susan; Faderl Stefan; Estrov Zeev; Giles Francis; Murgo Anthony; Ladie Nakia; Verstovsek Srdan; Cortes Jorge
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
Cancer 2007;109(2):248-55.
2007: Kantarjian Hagop M; O'Brien Susan; Shan Jianqin; Aribi Ahmed; Garcia-Manero Guillermo; Jabbour Elias; Ravandi Farhad; Cortes Jorge; Davisson Jan; Issa Jean-Pierre
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Cancer 2007;109(2):265-73.
2007: Giles Francis J; Cortes Jorge; Jones Dan; Bergstrom Donald; Kantarjian Hagop; Freedman Steven J
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.
Blood 2007;109(2):500-2.
2007: Quintas-Cardama Alfonso; Kantarjian Hagop; Jones Dan; Nicaise Claude; O'Brien Susan; Giles Francis; Talpaz Moshe; Cortes Jorge
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
Blood 2007;109(2):497-9.
2007: Kantarjian Hagop; Oki Yasuhiro; Garcia-Manero Guillermo; Huang Xuelin; O'Brien Susan; Cortes Jorge; Faderl Stefan; Bueso-Ramos Carlos; Ravandi Farhad; Estrov Zeev; Ferrajoli Alessandra; Wierda William; Shan Jianqin; Davis Jan; Giles Francis; Saba Hussain I; Issa Jean-Pierre J
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Blood 2007;109(1):52-7.
2006: Kantarjian Hagop M; Talpaz Moshe; Giles Francis; O'Brien Susan; Cortes Jorge
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.
Annals of internal medicine 2006;145(12):913-23.
2006: Quintás-Cardama Alfonso; Kantarjian Hagop; Cortes Jorge
Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.
Future oncology (London, England) 2006;2(6):655-65.
2006: Verstovsek Srdan; Giles Francis J; Quintás-Cardama Alfonso; Manshouri Taghi; Huynh Ly; Manley Paul; Cortes Jorge; Tefferi Ayalew; Kantarjian Hagop
Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells.
Leukemia research 2006;30(12):1499-505.
2006: Jabbour Elias; Cortes Jorge; Kantarjian Hagop
Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Current opinion in oncology 2006;18(6):578-83.
2006: Garcia-Manero Guillermo; Kantarjian Hagop M; Sanchez-Gonzalez Blanca; Yang Hui; Rosner Gary; Verstovsek Srdan; Rytting Michael; Wierda William G; Ravandi Farhad; Koller Charles; Xiao Lianchun; Faderl Stefan; Estrov Zeev; Cortes Jorge; O'brien Susan; Estey Elihu; Bueso-Ramos Carlos; Fiorentino Jackie; Jabbour Elias; Issa Jean-Pierre
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Blood 2006;108(10):3271-9.
2006: Verstovsek Srdan; Akin Cem; Manshouri Taghi; Quintás-Cardama Alfonso; Huynh Ly; Manley Paul; Tefferi Ayalew; Cortes Jorge; Giles Francis J; Kantarjian Hagop
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.
Leukemia research 2006;30(11):1365-70.
2006: Quintas-Cardama Alfonso; Kantarjian Hagop; O'Brien Susan; Jabbour Elias; Giles Francis; Ravandi Farhad; Faderl Stefan; Pierce Sherry; Shan Jenny; Verstovsek Srdan; Cortes Jorge
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Cancer 2006;107(7):1525-9.
2006: Quintas-Cardama Alfonso; Aribi Ahmed; Cortes Jorge; Giles Francis J; Kantarjian Hagop; Verstovsek Srdan
Novel approaches in the treatment of systemic mastocytosis.
Cancer 2006;107(7):1429-39.
2006: Jabbour E; Kantarjian H; Jones D; Talpaz M; Bekele N; O'Brien S; Zhou X; Luthra R; Garcia-Manero G; Giles F; Rios M B; Verstovsek S; Cortes J
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(10):1767-73.
2006: Kovitz Craig; Kantarjian Hagop; Garcia-Manero Guillermo; Abruzzo Lynne V; Cortes Jorge
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.
Blood 2006;108(8):2811-3.
2006: Arana-Yi Cecilia; Quintás-Cardama Alfonso; Giles Francis; Thomas Deborah; Carrasco-Yalan Antonio; Cortes Jorge; Kantarjian Hagop; Verstovsek Srdan
Advances in the therapy of chronic idiopathic myelofibrosis.
The oncologist 2006;11(8):929-43.
2006: Kantarjian Hagop M; Talpaz Moshe; O'Brien Susan; Jones Daniel; Giles Francis; Garcia-Manero Guillermo; Faderl Stefan; Ravandi Farhad; Rios Mary Beth; Shan Jianqin; Cortes Jorge
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
Blood 2006;108(6):1835-40.
2006: Giles Francis; Fischer Thomas; Cortes Jorge; Garcia-Manero Guillermo; Beck Joachim; Ravandi Farhad; Masson Eric; Rae Patricia; Laird Glen; Sharma Sunil; Kantarjian Hagop; Dugan Margaret; Albitar Maher; Bhalla Kapil
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(15):4628-35.
2006: Jabbour Elias; Cortes Jorge; Kantarjian Hagop M; Giralt Sergio; Jones Dan; Jones Roy; Giles Francis; Andersson Borje S; Champlin Richard; de Lima Marcos
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Blood 2006;108(4):1421-3.
2006: Yee Karen W L; Cortes Jorge; Ferrajoli Alessandra; Garcia-Manero Guillermo; Verstovsek Srdan; Wierda William; Thomas Deborah; Faderl Stefan; King Ivan; O'brien Susan M; Jeha Sima; Andreeff Michael; Cahill Ann; Sznol Mario; Giles Francis J
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
Leukemia research 2006;30(7):813-22.
2006: Faderl Stefan; Verstovsek Srdan; Cortes Jorge; Ravandi Farhad; Beran Miloslav; Garcia-Manero Guillermo; Ferrajoli Alessandra; Estrov Zeev; O'Brien Susan; Koller Charles; Giles Francis J; Wierda William; Kwari Monica; Kantarjian Hagop M
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
Blood 2006;108(1):45-51.
2006: Kantarjian Hagop; Giles Francis; Wunderle Lydia; Bhalla Kapil; O'Brien Susan; Wassmann Barbara; Tanaka Chiaki; Manley Paul; Rae Patricia; Mietlowski William; Bochinski Kathy; Hochhaus Andreas; Griffin James D; Hoelzer Dieter; Albitar Maher; Dugan Margaret; Cortes Jorge; Alland Leila; Ottmann Oliver G
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
The New England journal of medicine 2006;354(24):2542-51.
2006: Talpaz Moshe; Shah Neil P; Kantarjian Hagop; Donato Nicholas; Nicoll John; Paquette Ron; Cortes Jorge; O'Brien Susan; Nicaise Claude; Bleickardt Eric; Blackwood-Chirchir M Anne; Iyer Vishwanath; Chen Tai-Tsang; Huang Fei; Decillis Arthur P; Sawyers Charles L
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
The New England journal of medicine 2006;354(24):2531-41.
2006: Tibes Raoul; Keating Michael J; Ferrajoli Alessandra; Wierda William; Ravandi Farhad; Garcia-Manero Guillermo; O'Brien Susan; Cortes Jorge; Verstovsek Srdan; Browning Mary L; Faderl Stefan
Activity of alemtuzumab in patients with CD52-positive acute leukemia.
Cancer 2006;106(12):2645-51.
2006: Kantarjian Hagop M; Cortes Jorge
New strategies in chronic myeloid leukemia.
International journal of hematology 2006;83(4):289-93.
2006: Quintás-Cardama Alfonso; Cortes Jorge
Kinase inhibitors in chronic myelogenous leukemia.
Clinical advances in hematology & oncology : H&O 2006;4(5):365-74.
2006: Yin C Cameron; Cortes Jorge; Barkoh Bedia; Hayes Kimberly; Kantarjian Hagop; Jones Dan
t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
Cancer 2006;106(8):1730-8.
2006: Thomas Deborah A; Faderl Stefan; O'Brien Susan; Bueso-Ramos Carlos; Cortes Jorge; Garcia-Manero Guillermo; Giles Francis J; Verstovsek Srdan; Wierda William G; Pierce Sherry A; Shan Jianqin; Brandt Mark; Hagemeister Fredrick B; Keating Michael J; Cabanillas Fernando; Kantarjian Hagop
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Cancer 2006;106(7):1569-80.
2006: Cortes Jorge
Overcoming drug resistance in chronic myeloid leukemia.
Current opinion in hematology 2006;13(2):79-86.
2006: Ault Patricia; Kantarjian Hagop; O'Brien Susan; Faderl Stefan; Beran Miloslav; Rios Mary Beth; Koller Charles; Giles Francis; Keating Michael; Talpaz Moshe; Cortes Jorge
Pregnancy among patients with chronic myeloid leukemia treated with imatinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(7):1204-8.
2006: Kantarjian Hagop; Beran Miloslav; Cortes Jorge; O'Brien Susan; Giles Francis; Pierce Sherry; Shan Jianqin; Plunkett William; Keating Michael; Estey Elihu
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Cancer 2006;106(5):1099-109.
2006: Kantarjian Hagop; O'brien Susan; Cortes Jorge; Giles Francis; Faderl Stefan; Jabbour Elias; Garcia-Manero Guillermo; Wierda William; Pierce Sherry; Shan Jianqin; Estey Elihu
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.
Cancer 2006;106(5):1090-8.
2006: Sampath Deepa; Cortes Jorge; Estrov Zeev; Du Min; Shi Zheng; Andreeff Michael; Gandhi Varsha; Plunkett William
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.
Blood 2006;107(6):2517-24.
2006: Oki Yasuhiro; Kantarjian Hagop M; Zhou Xian; Cortes Jorge; Faderl Stefan; Verstovsek Srdan; O'Brien Susan; Koller Charles; Beran Miloslav; Bekele B Nebiyou; Pierce Sherry; Thomas Deborah; Ravandi Farhad; Wierda William G; Giles Francis; Ferrajoli Alessandra; Jabbour Elias; Keating Michael J; Bueso-Ramos Carlos E; Estey Elihu; Garcia-Manero Guillermo
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
Blood 2006;107(3):880-4.
2006: Mattiuzzi Gloria N; Alvarado Gladys; Giles Francis J; Ostrosky-Zeichner Luis; Cortes Jorge; O'brien Susan; Verstovsek Srdan; Faderl Stefan; Zhou Xian; Raad Issam I; Bekele B Nebiyou; Leitz G J; Lopez-Roman Ivonne; Estey Elihu H
Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies.
Antimicrobial agents and chemotherapy 2006;50(1):143-7.
2006: Wierda William; O'brien Susan; Faderl Stefan; Ferrajoli Alessandra; Wang Xuemei; Do Kim-Anh; Garcia-Manero Guillermo; Thomas Deborah; Cortes Jorge; Ravandi-Kashani Farhad; Giles Francis; Lerner Susan; Kantarjian Hagop; Keating Michael
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.
Cancer 2006;106(2):337-45.
2006: Borthakur Gautam; Kantarjian Hagop; Daley George; Talpaz Moshe; O'Brien Susan; Garcia-Manero Guillermo; Giles Francis; Faderl Stefan; Sugrue Mary; Cortes Jorge
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
Cancer 2006;106(2):346-52.
2006: Thomas Deborah A; Sarris Andreas H; Cortes Jorge; Faderl Stefan; O'Brien Susan; Giles Francis J; Garcia-Manero Guillermo; Rodriguez Maria A; Cabanillas Fernando; Kantarjian Hagop
Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia.
Cancer 2006;106(1):120-7.
2006: Jabbour Elias; Kantarjian Hagop; O'Brien Susan; Rios Mary Beth; Abruzzo Lynne; Verstovsek Srdan; Garcia-Manero Guillermo; Cortes Jorge
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.
Blood 2006;107(2):480-2.
2005: Ravandi Farhad; O'Brien Susan; Jones Dan; Lerner Susan; Faderl Stefan; Ferrajoli Alessandra; Wierda William; Garcia-Manero Guillermo; Thomas Deborah; Koller Charles; Verstovsek Srdan; Giles Francis; Cortes Jorge; Herling Marco; Kantarjian Hagop; Keating Michael
T-cell prolymphocytic leukemia: a single-institution experience.
Clinical lymphoma & myeloma 2005;6(3):234-9.
2005: Giles Francis; Verstovsek Srdan; Thomas Deborah; Gerson Stanton; Cortes Jorge; Faderl Stefan; Ferrajoli Alessandra; Ravandi Farhad; Kornblau Steven; Garcia-Manero Guillermo; Jabbour Elias; O'Brien Susan; Karsten Verena; Cahill Ann; Yee Karen; Albitar Maher; Sznol Mario; Kantarjian Hagop
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7817-24.
2005: Merzianu Mihai; Medeiros L Jeffrey; Cortes Jorge; Yin Cameron; Lin Pei; Jones Dan; Glassman Armand; Kantarjian Hagop; Huh Yang
inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases.
American journal of clinical pathology 2005;124(5):807-14.
2005: Yee Karen W L; Hagey Anne; Verstovsek Srdan; Cortes Jorge; Garcia-Manero Guillermo; O'Brien Susan M; Faderl Stefan; Thomas Deborah; Wierda William; Kornblau Steven; Ferrajoli Alessandra; Albitar Maher; McKeegan Evelyn; Grimm David R; Mueller Toby; Holley-Shanks Rhonda R; Sahelijo Leonardo; Gordon Gary B; Kantarjian Hagop M; Giles Francis J
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(18):6615-24.
2005: Cortes Jorge; Kantarjian Hagop
New targeted approaches in chronic myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(26):6316-24.
2005: Talpaz Moshe; Rakhit Ashok; Rittweger Karen; O'Brien Susan; Cortes Jorge; Fettner Scott; Hooftman Leon; Kantarjian Hagop
Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(17):6247-55.
2005: Verstovsek Srdan; Golemovic Mirna; Kantarjian Hagop; Manshouri Tashi; Estrov Zeev; Manley Paul; Sun Tong; Arlinghaus Ralph B; Alland Leila; Dugan Margaret; Cortes Jorge; Giles Francis; Beran Miloslav
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.
Cancer 2005;104(6):1230-6.
2005: Jabbour Elias; Verstovsek Srdan; Giles Francis; Gandhi Varsha; Cortes Jorge; O'Brien Susan; Plunkett William; Garcia-Manero Guillermo; Jackson C Ellen; Kantarjian Hagop; Andreeff Michael
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.
Cancer 2005;104(3):541-6.
2005: Giles Francis; O'Brien Susan; Cortes Jorge; Verstovsek Srdan; Bueso-Ramos Carlos; Shan Jianqin; Pierce Sherry; Garcia-Manero Guillermo; Keating Michael; Kantarjian Hagop
Outcome of patients with acute myelogenous leukemia after second salvage therapy.
Cancer 2005;104(3):547-54.
2005: Kantarjian Hagop M; Bueso-Ramos Carlos E; Talpaz Moshe; O'Brien Susan; Giles Francis; Faderl Stefan; Wierda William; Rios Mary Beth; Shan Jianqin; Cortes Jorge
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
Cancer 2005;104(4):777-80.
2005: Kantarjian Hagop M; Bueso-Ramos Carlos E; Talpaz Moshe; O'Brien Susan; Giles Francis; Rios Mary Beth; Shan Jianqin; Cortes Jorge
The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy.
Leukemia & lymphoma 2005;46(7):993-7.
2005: Golemovic Mirna; Verstovsek Srdan; Giles Francis; Cortes Jorge; Manshouri Taghi; Manley Paul W; Mestan Jürgen; Dugan Margaret; Alland Leila; Griffin James D; Arlinghaus Ralph B; Sun Tong; Kantarjian Hagop; Beran Miloslav
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13):4941-7.
2005: Issa Jean-Pierre J; Gharibyan Vazganush; Cortes Jorge; Jelinek Jaroslav; Morris Gail; Verstovsek Srdan; Talpaz Moshe; Garcia-Manero Guillermo; Kantarjian Hagop M
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(17):3948-56.
2005: Saba Rashid; Jabbour Elias; Giles Francis; Cortes Jorge; Talpaz Moshe; O'Brien Susan; Freireich Emil J; Garcia-Manero Guillermo; Kantarjian Hagop; Verstovsek Srdan
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986.
Cancer 2005;103(12):2551-7.
2005: Keating Michael J; O'Brien Susan; Albitar Maher; Lerner Susan; Plunkett William; Giles Francis; Andreeff Michael; Cortes Jorge; Faderl Stefan; Thomas Deborah; Koller Charles; Wierda William; Detry Michelle A; Lynn Alice; Kantarjian Hagop
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4079-88.
2005: Wierda William; O'Brien Susan; Wen Sijin; Faderl Stefan; Garcia-Manero Guillermo; Thomas Deborah; Do Kim-Anh; Cortes Jorge; Koller Charles; Beran Miloslav; Ferrajoli Alessandra; Giles Francis; Lerner Susan; Albitar Maher; Kantarjian Hagop; Keating Michael
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4070-8.
2005: Cortes Jorge; Talpaz Moshe; O'Brien Susan; Jones Dan; Luthra Rajyalakshmi; Shan Jenny; Giles Francis; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Rios Mary B; Kantarjian Hagop
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3425-32.
2005: Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Giles Francis; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Shan Jianqin; Rios Mary Beth; Champlin Richard; de Lima Marcos; Cortes Jorge
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
Cancer 2005;103(10):2099-108.
2005: Cortes Jorge; Faderl Stefan; Estey Elihu; Kurzrock Razelle; Thomas Deborah; Beran Miloslav; Garcia-Manero Guillermo; Ferrajoli Alessandra; Giles Francis; Koller Charles; O'Brien Susan; Wright John; Bai Stephen A; Kantarjian Hagop
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(12):2805-12.
2005: Quintas-Cardama Alfonso; Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Garcia-Manero Guillermo; Verstovsek Srdan; Rios Mary Beth; Hayes Kimberly; Glassman Armand; Bekele B Nebiyou; Zhou Xian; Cortes Jorge
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
Blood 2005;105(6):2281-6.
2005: Faderl Stefan; Gandhi Varsha; O'Brien Susan; Bonate Peter; Cortes Jorge; Estey Elihu; Beran Miloslav; Wierda William; Garcia-Manero Guillermo; Ferrajoli Alessandra; Estrov Zeev; Giles Francis J; Du Min; Kwari Monica; Keating Michael; Plunkett William; Kantarjian Hagop
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
Blood 2005;105(3):940-7.
2005: Tsimberidou A-M; Giles F J; Khouri I; Bueso-Ramos C; Pilat S; Thomas D A; Cortes J; Kurzrock R
Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(1):139-45.
2004: Kantarjian Hagop; Thomas Deborah; O'Brien Susan; Cortes Jorge; Giles Francis; Jeha Sima; Bueso-Ramos Carlos E; Pierce Sherry; Shan Jianqin; Koller Charles; Beran Miloslav; Keating Michael; Freireich Emil J
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
Cancer 2004;101(12):2788-801.
2004: Jabbour Elias; Kantarjian Hagop; Cortes Jorge
Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
Leukemia & lymphoma 2004;45(11):2187-95.
2004: Hennessy Bryan; Giles Francis; Cortes Jorge; O'brien Susan; Ferrajoli Alessandra; Ossa Gladys; Garcia-Manero Guillermo; Faderl Stefan; Kantarjian Hagop; Verstovsek Srdan
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
American journal of hematology 2004;77(3):209-14.
2004: Thomas Deborah A; O'Brien Susan; Cortes Jorge; Giles Francis J; Faderl Stefan; Verstovsek Srdan; Ferrajoli Alessandra; Koller Charles; Beran Miloslav; Pierce Sherry; Ha Chul S; Cabanillas Fernando; Keating Michael J; Kantarjian Hagop
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
Blood 2004;104(6):1624-30.
2004: de Lima Marcos; Anagnostopoulos Athanasios; Munsell Mark; Shahjahan Munir; Ueno Naoto; Ippoliti Cindy; Andersson Borje S; Gajewski James; Couriel Daniel; Cortes Jorge; Donato Michele; Neumann Joyce; Champlin Richard; Giralt Sergio
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation.
Blood 2004;104(3):865-72.
2004: Bueso-Ramos Carlos E; Cortes Jorge; Talpaz Moshe; O'Brien Susan; Giles Francis; Rios Mary Beth; Medeiros L Jeffrey; Kantarjian Hagop
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.
Cancer 2004;101(2):332-6.
2004: Cortes Jorge; O'Dwyer Michael E
Clonal evolution in chronic myelogenous leukemia.
Hematology/oncology clinics of North America 2004;18(3):671-84, x.
2004: Cortes Jorge
Natural history and staging of chronic myelogenous leukemia.
Hematology/oncology clinics of North America 2004;18(3):569-84, viii.
2004: Quintas-Cardama Alfonso; Kantarjian Hagop; O'Brien Susan; Garcia-Manero Guillermo; Rios Mary B; Talpaz Moshe; Cortes Jorge
Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia.
Cancer 2004;100(12):2592-7.
2004: Cortes Jorge; O'Brien Susan; Quintas Alfonso; Giles Francis; Shan Jianquin; Rios Mary Beth; Talpaz Moshe; Kantarjian Hagop
Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
Cancer 2004;100(11):2396-402.
2004: Tsimberidou Apostolia-Maria; Medina Jorge; Cortes Jorge; Rios Adan; Bonnie Glisson; Faderl Stefan; Kantarjian Hagop; Garcia-Manero Guillermo
Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature.
Leukemia research 2004;28(6):657-60.
2004: Ault Patricia; Kantarjian Hagop; Welch Mary Alma; Giles Francis; Rios Mary Beth; Cortes Jorge
Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia.
Leukemia research 2004;28(6):613-8.
2004: Thomas Deborah A; Faderl Stefan; Cortes Jorge; O'Brien Susan; Giles Francis J; Kornblau Steven M; Garcia-Manero Guillermo; Keating Michael J; Andreeff Michael; Jeha Sima; Beran Miloslav; Verstovsek Srdan; Pierce Sherry; Letvak Laurie; Salvado August; Champlin Richard; Talpaz Moshe; Kantarjian Hagop
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
Blood 2004;103(12):4396-407.
2004: Cortes Jorge; Thomas Deborah; Koller Charles; Giles Francis; Estey Elihu; Faderl Stefan; Garcia-Manero Guillermo; McConkey David; Ruiz Stacey L; Guerciolini Roberto; Wright John; Kantarjian Hagop
Phase I study of bortezomib in refractory or relapsed acute leukemias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3371-6.
2004: Cortes Jorge; Kantarjian Hagop
Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cancer 2004;100(10):2064-78.
2004: Giles Francis; Thomas Deborah; Garcia-Manero Guillermo; Faderl Stefan; Cortes Jorge; Verstovsek Srdan; Ferrajoli Alessandra; Jeha Sima; Beran Miloslav; Koller Charles; Andreeff Michael; Cahill Ann; Clairmont Caroline; Sznol Mario; Kantarjian Hagop
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(9):2908-17.
2004: Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Garcia-Manero Guillermo; Verstovsek Srdan; Giles Francis; Rios Mary Beth; Shan Jianqin; Letvak Laurie; Thomas Deborah; Faderl Stefan; Ferrajoli Alessandra; Cortes Jorge
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Blood 2004;103(8):2873-8.
2004: Giles Francis J; Kantarjian Hagop; Cortes Jorge
Novel therapies for patients with chronic myeloid leukemia.
Expert review of anticancer therapy 2004;4(2):271-82.
2004: Orsolic Nada; Giles Francis J; Gourdeau Henriette; Golemovic Mirna; Beran Miloslav; Cortes Jorge; Freireich Emil J; Kantarjian Hagop; Verstovsek Srdan
Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation.
British journal of haematology 2004;124(6):727-38.
2004: Issa Jean-Pierre J; Garcia-Manero Guillermo; Giles Francis J; Mannari Rajan; Thomas Deborah; Faderl Stefan; Bayar Emel; Lyons John; Rosenfeld Craig S; Cortes Jorge; Kantarjian Hagop M
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
Blood 2004;103(5):1635-40.
2004: Mattiuzzi Gloria N; Kantarjian Hagop; O'Brien Susan; Kontoyiannis Dimitrios P; Giles Francis; Zhou Xian; Lim JoAnn; Bekele B Nebiyou; Faderl Stefan; Cortes Jorge; Pierce Sherry; Leitz Gerhard J; Raad Issam; Estey Elihu
Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy.
Cancer 2004;100(3):568-73.
2004: Ravandi Farhad; Kantarjian Hagop; Giles Francis; Cortes Jorge
New agents in acute myeloid leukemia and other myeloid disorders.
Cancer 2004;100(3):441-54.
2004: Kantarjian Hagop; O'Brien Susan; Cortes Jorge; Giles Francis; Shan Jianqin; Rios Mary Beth; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Wierda William; Kornblau Steven; Ferrajoli Alessandra; Keating Michael; Talpaz Moshe
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):68-75.
2004: Ravandi Farhad; Cortes Jorge
Investigational agents in myeloid disorders.
Advances in pharmacology (San Diego, Calif.) 2004;51():59-97.
2003: O'Brien Susan M; Kantarjian Hagop M; Thomas Deborah A; Cortes Jorge; Giles Francis J; Wierda William G; Koller Charles A; Ferrajoli Alessandra; Browning Mary; Lerner Susan; Albitar Maher; Keating Michael J
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
Cancer 2003;98(12):2657-63.
2003: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge; Giles Francis J; Rios Mary Beth; Shan Jianqin; Faderl Stefan; Garcia-Manero Guillermo; Ferrajoli Alessandra; Verstovsek Srdan; Wierda William; Keating Michael; Talpaz Moshe
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Cancer 2003;98(12):2636-42.
2003: Tsao Anne S; Kantarjian Hagop; Cortes Jorge; O'Brien Susan; Talpaz Moshe
Imatinib mesylate causes hypopigmentation in the skin.
Cancer 2003;98(11):2483-7.
2003: Thomas Deborah A; O'Brien Susan; Bueso-Ramos Carlos; Faderl Stefan; Keating Michael J; Giles Francis J; Cortes Jorge; Kantarjian Hagop M
Rituximab in relapsed or refractory hairy cell leukemia.
Blood 2003;102(12):3906-11.
2003: Medina Jorge; Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Garcia-Manero Guillermo; Giles Francis; Rios Mary Beth; Hayes Kimberly; Cortes Jorge
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
Cancer 2003;98(9):1905-11.
2003: Estey Elihu H; Thall Peter F; Wang Xuemei; Verstovsek Srdan; Cortes Jorge; Kantarjian Hagop M
Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML.
Blood 2003;102(9):3097-9.
2003: Cortes Jorge; Giles Francis
New agents in chronic myelogenous leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN 2003;1(4):501-12.
2003: Tsimberidou Apostolia; Cortes Jorge; Thomas Deborah; Garcia-Manero Guillermo; Verstovsek Srdan; Faderl Stephan; Albitar Maher; Kantarjian Hagop; Estey Elihu; Giles Francis J
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Leukemia research 2003;27(10):893-7.
2003: Apostolidou Efrosyni; Cortes Jorge; Tsimberidou Apostolia; Estey Elihu; Kantarjian Hagop; Giles Francis J
Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia.
Leukemia research 2003;27(10):887-91.
2003: Cortes Jorge; Talpaz Moshe; O'Brien Susan; Giles Francis; Beth Rios Mary; Shan Jianquin; Faderl Stefan; Garcia-Manero Guillermo; Ferrajoli Alessandra; Wierda William; Kantarjian Hagop
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cancer 2003;98(6):1105-13.
2003: O'Brien Susan; Giles Francis; Talpaz Moshe; Cortes Jorge; Rios Mary Beth; Shan Jianqin; Thomas Deborah; Andreeff Michael; Kornblau Steven; Faderl Stefan; Garcia-Manero Guillermo; White Kevin; Mallard Susie; Freireich Emil; Kantarjian Hagop M
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
Cancer 2003;98(5):888-93.
2003: Cortes Jorge
Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Clinical lymphoma 2003;4 Suppl 1():S30-5.
2003: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge; Giles Francis J; Faderl Stefan; Issa Jean-Pierre; Garcia-Manero Guillermo; Rios Mary Beth; Shan Jianqin; Andreeff Michael; Keating Michael; Talpaz Moshe
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
Cancer 2003;98(3):522-8.
2003: Garcia-Manero Guillermo; Faderl Stefan; O'Brien Susan; Cortes Jorge; Talpaz Moshe; Kantarjian Hagop M
Chronic myelogenous leukemia: a review and update of therapeutic strategies.
Cancer 2003;98(3):437-57.
2003: Kantarjian Hagop; O'Brien Susan; Cortes Jorge; Giles Francis; Thomas Deborah; Kornblau Steven; Shan Jianquin; Beth Rios Mary; Keating Michael; Freireich Emil; Talpaz Moshe
Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications.
Cancer 2003;98(1):81-5.
2003: Verstovsek Srdan; Lunin Scott; Kantarjian Hagop; Manshouri Taghi; Faderl Stefan; Cortes Jorge; Giles Francis; Albitar Maher
Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia.
Leukemia research 2003;27(7):661-9.
2003: Cortes Jorge; Giles Francis; O'Brien Susan; Thomas Deborah; Garcia-Manero Guillermo; Rios Mary Beth; Faderl Stefan; Verstovsek Srdan; Ferrajoli Alessandra; Freireich Emil J; Talpaz Moshe; Kantarjian Hagop
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
Blood 2003;102(1):83-6.
2003: Garcia-Manero Guillermo; Talpaz Moshe; Giles Francis J; Cortes Jorge; Faderl Stefan; O'Brien Susan; Thomas Deborah; Verstovsek Srdan; Beth Rios Mary; Shan Jianquin; Ferrajoli Alessandra; Wierda William; Kantarjian Hagop M
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
Cancer 2003;97(12):3010-6.
2003: Cortes Jorge; Giles Francis; O'Brien Susan; Thomas Deborah; Albitar Maher; Rios Mary Beth; Talpaz Moshe; Garcia-Manero Guillermo; Faderl Stefan; Letvak Laurie; Salvado August; Kantarjian Hagop
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cancer 2003;97(11):2760-6.
2003: Estey Elihu; Giles Francis; Cortes Jorge; Beran Miloslav; Verstovsek Srdan; Garcia-Manero Guillermo; Faderl Stefan; Kantarjian Hagop
Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML.
Leukemia research 2003;27(6):475-9.
2003: Cortes Jorge; Ault Patricia; Koller Charles; Thomas Deborah; Ferrajoli Alessandra; Wierda William; Rios Mary B; Letvak Laurie; Kaled Elizabeth S; Kantarjian Hagop
Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.
Blood 2003;101(12):4714-6.
2003: Cortes Jorge
CMML: a biologically distinct myeloproliferative disease.
Current hematology reports 2003;2(3):202-8.
2003: Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Giles Francis; Rios Mary Beth; White Kevin; Garcia-Manero Guillermo; Ferrajoli Alessandra; Verstovsek Srdan; Wierda William; Kornblau Steven; Cortes Jorge
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cancer 2003;97(9):2225-8.
2003: Lazo Guillermo; Kantarjian Hagop; Estey Elihu; Thomas Deborah; O'Brien Susan; Cortes Jorge
Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
Cancer 2003;97(9):2218-24.
2003: Verstovsek Srdan; Manshouri Taghi; Smith Franklin O; Giles Francis J; Cortes Jorge; Estey Elihu; Kantarjian Hagop; Keating Michael; Jeha Sima; Albitar Maher
Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia.
Cancer 2003;97(9):2212-7.
2003: Faderl Stefan; Thomas Deborah A; O'Brien Susan; Garcia-Manero Guillermo; Kantarjian Hagop M; Giles Francis J; Koller Charles; Ferrajoli Alessandra; Verstovsek Srdan; Pro Barbara; Andreeff Michael; Beran Miloslav; Cortes Jorge; Wierda William; Tran Ngoc; Keating Michael J
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
Blood 2003;101(9):3413-5.
2003: Tsimberidou Apostolia M; Kantarjian Hagop M; Cortes Jorge; Thomas Deborah A; Faderl Stefan; Garcia-Manero Guillermo; Verstovsek Srdan; Ferrajoli Alessandra; Wierda William; Alvarado Yesid; O'Brien Susan M; Albitar Maher; Keating Michael J; Giles Francis J
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Cancer 2003;97(7):1711-20.
2003: Apostolidou Efrosyni; Estey Elihu; Cortes Jorge; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah; Tsimberidou Apostolia; Kantarjian Hagop; Giles Francis J
Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia.
Leukemia research 2003;27(4):301-4.
2003: Kantarjian Hagop M; Gandhi Varsha; Kozuch Peter; Faderl Stefan; Giles Francis; Cortes Jorge; O'Brien Susan; Ibrahim Nuhad; Khuri Fadlo; Du Min; Rios Mary Beth; Jeha Sima; McLaughlin Peter; Plunkett William; Keating Michael
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1167-73.
2003: Tsimberidou Apostolia; Estey Elihu; Cortes Jorge; Thomas Deborah; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Keating Michael; Albitar Maher; O'Brien Susan; Kantarjian Hagop; Giles Francis
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
Cancer 2003;97(6):1481-7.
2003: Verstovsek Srdan; Kantarjian Hagop; Manshouri Taghi; Cortes Jorge; Faderl Stefan; Giles Francis J; Keating Michael; Albitar Maher
Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia.
Cancer 2003;97(5):1248-52.
2003: Cortes Jorge; Kantarjian Hagop; Albitar Maher; Thomas Deborah; Faderl Stefan; Koller Charles; Garcia-Manero Guillermo; Giles Francis; Andreeff Michael; O'Brien Susan; Keating Michael; Estey Elihu
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Cancer 2003;97(5):1234-41.
2003: Cortes Jorge; Albitar Maher; Thomas Deborah; Giles Francis; Kurzrock Razelle; Thibault Alain; Rackoff Wayne; Koller Charles; O'Brien Susan; Garcia-Manero Guillermo; Talpaz Moshe; Kantarjian Hagop
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.
Blood 2003;101(5):1692-7.
2003: Cortes Jorge; Kantarjian Hagop
Advanced-phase chronic myeloid leukemia.
Seminars in hematology 2003;40(1):79-86.
2003: Mattiuzzi Gloria N; Estey Elihu; Raad Issam; Giles Francis; Cortes Jorge; Shen Yu; Kontoyiannis Dimitrios; Koller Charles; Munsell Mark; Beran Miloslav; Kantarjian Hagop
Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Cancer 2003;97(2):450-6.
2003: Alvarado Yesid; Tsimberidou Apostolia; Kantarjian Hagop; Cortes Jorge; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah; Estey Elihu; Giles Francis J
Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
Cancer chemotherapy and pharmacology 2003;51(1):87-90.
2003: Alvarado Yesid; Cortes Jorge; Verstovsek Srdan; Thomas Deborah; Faderl Stephan; Estrov Zeev; Kantarjian Hagop; Giles Francis J
Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia.
Cancer chemotherapy and pharmacology 2003;51(1):81-6.
2003: Kantarjian Hagop M; Talpaz Moshe; O'Brien Susan; Giles Francis; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah; Shan Jianqin; Rios Mary Beth; Cortes Jorge
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.
Blood 2003;101(2):473-5.
2002: Thomas Deborah A; Cortes Jorge; Kantarjian Hagop M
New agents in the treatment of acute lymphocytic leukaemia.
Best practice & research. Clinical haematology 2002;15(4):771-90.
2002: Cortes Jorge; Tsimberidou Apostolia M; Alvarez Ricardo; Thomas Deborah; Beran Miloslav; Kantarjian Hagop; Estey Elihu; Giles Francis J
Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.
Cancer chemotherapy and pharmacology 2002;50(6):497-500.
2002: Kurzrock Razelle; Cortes Jorge; Kantarjian Hagop
Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome.
Seminars in hematology 2002;39(4 Suppl 3):20-4.
2002: Jilani Iman; Estey Elihu; Huh Yang; Joe Youngson; Manshouri Taghi; Yared Marwan; Giles Francis; Kantarjian Hagop; Cortes Jorge; Thomas Deborah; Keating Michael; Freireich Emil; Albitar Maher
Differences in CD33 intensity between various myeloid neoplasms.
American journal of clinical pathology 2002;118(4):560-6.
2002: Ault Patricia; Cortes Jorge; Koller Charles; Kaled Elizabeth S; Kantarjian Hagop
Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.
Leukemia research 2002;26(9):881-4.
2002: Garcia-Manero Guillermo; Faderl Stefan; Giles Francis; Thomas Deborah; Cortes Jorge; O'Brien Susan; Davis Jan; Kantarjian Hagop M; Estey Elihu
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
Haematologica 2002;87(8):804-7.
2002: Verstovsek Srdan; Estey Elihu; Manshouri Taghi; Giles Francis J; Cortes Jorge; Beran Miloslav; Rogers Anna; Keating Michael; Kantarjian Hagop; Albitar Maher
Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome.
British journal of haematology 2002;118(1):151-6.
2002: Dabaja Bouthaina S; Ha Chul S; Thomas Deborah A; Wilder Richard B; Gopal Ramesh; Cortes Jorge; Bueso-Ramos Carlos; Hess Mark A; Cox James D; Kantarjian Hagop M
The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma.
Cancer 2002;94(10):2738-44.
2002: Verstovsek Srdan; Lin Hui; Kantarjian Hagop; Saglio Giuseppe; De Micheli Daniela; Pane Fabrizio; Garcia-Manero Guillermo; Intrieri Mariano; Rotoli Bruno; Salvatore Francesco; Guo Jie Q; Talpaz Moshe; Specchia Giorgina; Pizzolo Gianni; Liberati Anna Marina; Cortes Jorge; Quackenbush Robert C; Arlinghaus Ralph B
Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course.
Cancer 2002;94(9):2416-25.
2002: Kantarjian Hagop M; Cortes Jorge; O'Brien Susan; Giles Francis J; Albitar Maher; Rios Mary Beth; Shan Jianqin; Faderl Stefan; Garcia-Manero Guillermo; Thomas Deborah A; Resta Debra; Talpaz Moshe
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Blood 2002;99(10):3547-53.
2002: O'Brien Susan; Talpaz Moshe; Cortes Jorge; Shan Jianqin; Giles Francis J; Faderl Stefan; Thomas Deborah; Garcia-Manero Guillermo; Mallard Susie; Beth Mary; Koller Charles; Kornblau Steve; Andreeff Michael; Murgo Anthony; Keating Michael; Kantarjian Hagop M
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
Cancer 2002;94(7):2024-32.
2002: Verstovsek Srdan; Kantarjian Hagop; Manshouri Taghi; O'Brien Susan; Faderl Stefan; Talpaz Moshe; Cortes Jorge; Albitar Maher
Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia.
Cancer 2002;94(5):1517-21.
2002: Cortes Jorge; Thomas Deborah; Rios Adan; Koller Charles; O'Brien Susan; Jeha Sima; Faderl Stefan; Kantarjian Hagop
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.
Cancer 2002;94(5):1492-9.
2001: Kantarjian H M; Shan J; Smith T; Talpaz M; Kozuch P; Rios M B; Cortes J; Giles F J; O'Brien S
Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase.
Cancer 2001;92(10):2501-7.
2001: Kurzrock R; Cortes J; Thomas D A; Jeha S; Pilat S; Talpaz M
Pilot study of low-dose interleukin-11 in patients with bone marrow failure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(21):4165-72.
2001: Cortes J; O'Brien S; Loscertales J; Kantarjian H; Giles F; Thomas D; Koller C; Keating M
Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia.
Cancer 2001;92(8):2016-22.
2001: Beran M; Shen Y; Kantarjian H; O'Brien S; Koller C A; Giles F J; Cortes J; Thomas D A; Faderl S; Despa S; Estey E H
High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.
Cancer 2001;92(8):1999-2015.
2001: Talpaz M; O'Brien S; Rose E; Gupta S; Shan J; Cortes J; Giles F J; Faderl S; Kantarjian H M
Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.
Blood 2001;98(6):1708-13.
2001: Smith J A; Cortes J; Newman R A; Madden T L
Development of a simplified, sensitive high-performance liquid chromatographic method using fluorescence detection to determine the concentration of UCN-01 in human plasma.
Journal of chromatography. B, Biomedical sciences and applications 2001;760(2):247-53.
2001: Estey E; Koller C; Cortes J; Reed P; Freireich E; Giles F; Kantarjian H
Treatment of newly-diagnosed acute promyelocytic leukemia with liposomal all-trans retinoic acid.
Leukemia & lymphoma 2001;42(3):309-16.
2001: Cortes J; Estey E; O'Brien S; Giles F; Shen Y; Koller C; Beran M; Thomas D; Keating M; Kantarjian H
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia.
Cancer 2001;92(1):7-14.
2001: Ravandi F; Kantarjian H M; Talpaz M; O'Brien S; Faderl S; Giles F J; Thomas D; Cortes J; Andreeff M; Estrov Z; Rios M B; Albitar M
Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance.
Cancer 2001;91(11):1964-72.
2001: Ravandi F; Hayes K; Cortes J; Albitar M; Glassman A; Talpaz M; Kantarjian H M
Translocation t(17;18)(q10;q10): a new nonrandom chromosomal translocation of clonal evolution in chronic myeloid leukemia.
Cancer 2001;91(9):1704-8.
2001: O'Brien S M; Kantarjian H; Thomas D A; Giles F J; Freireich E J; Cortes J; Lerner S; Keating M J
Rituximab dose-escalation trial in chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(8):2165-70.
2001: O'Brien S M; Kantarjian H M; Cortes J; Beran M; Koller C A; Giles F J; Lerner S; Keating M
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1414-20.
2001: Fleming R V; Kantarjian H M; Husni R; Rolston K; Lim J; Raad I; Pierce S; Cortes J; Estey E
Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia.
Leukemia & lymphoma 2001;40(5-6):511-20.
2001: Cortes J
Central nervous system involvement in adult acute lymphocytic leukemia.
Hematology/oncology clinics of North America 2001;15(1):145-62.
2001: Giles F; Cortes J; Garcia-Manero G; Kornblau S; Estey E; Kwari M; Murgo A; Kantarjian H
Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.
Investigational new drugs 2001;19(1):13-20.
2000: Faderl S; Kantarjian H M; Estey E; Manshouri T; Chan C Y; Rahman Elsaied A; Kornblau S M; Cortes J; Thomas D A; Pierce S; Keating M J; Estrov Z; Albitar M
The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia.
Cancer 2000;89(9):1976-82.
2000: Kantarjian H M; Talpaz M; Smith T L; Cortes J; Giles F J; Rios M B; Mallard S; Gajewski J; Murgo A; Cheson B; O'Brien S
Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(20):3513-21.
2000: Kornblau S M; Vu H T; Ruvolo P; Estrov Z; O'Brien S; Cortes J; Kantarjian H; Andreeff M; May W S
BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1401-9.
2000: Cortes J; Kantarjian H M
Promising approaches in acute leukemia.
Investigational new drugs 2000;18(1):57-82.
2000: Ravandi-Kashani F; Cortes J; Giles F J
Myelodysplasia presenting as granulocytic sarcoma of mediastinum causing superior vena cava syndrome.
Leukemia & lymphoma 2000;36(5-6):631-7.
2000: Cortes J; Estey E; Beran M; O'Brien S; Giles F; Koller C; Keating M; Kantarjian H
Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia.
Leukemia & lymphoma 2000;36(5-6):479-84.
2000: Kantarjian H M; O'Brien S; Smith T L; Cortes J; Giles F J; Beran M; Pierce S; Huh Y; Andreeff M; Koller C; Ha C S; Keating M J; Murphy S; Freireich E J
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(3):547-61.
2000: Kaban K; Kantarjian H; Talpaz M; O'Brien S; Cortes J; Giles F J; Pierce S; Albitar M
Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy.
Cancer 2000;88(3):570-6.
2000: Faderl S; Kantarjian H M; Thomas D A; Cortes J; Giles F; Pierce S; Albitar M; Estrov Z
Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Leukemia & lymphoma 2000;36(3-4):263-73.
2000: Rodriguez J; Cortes J; Talpaz M; O'Brien S; Smith T L; Rios M B; Kantarjian H
Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):147-52.
1999: Kantarjian H M; Talpaz M; O'Brien S; Manshouri T; Cortes J; Giles F; Rios M B; Croce C M; Albitar M
Significance of FHIT expression in chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):4059-64.
1999: Sacchi S; Kantarjian H M; O'Brien S; Cortes J; Rios M B; Giles F J; Beran M; Koller C A; Keating M J; Talpaz M
Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.
Cancer 1999;86(12):2632-41.
1999: Ravandi F; Cortes J; Albitar M; Arlinghaus R; Qiang Guo J; Talpaz M; Kantarjian H M
Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance.
British journal of haematology 1999;107(3):581-6.
1999: Sacchi S; Kantarjian H M; Freireich E J; O'Brien S; Cortes J; Rios M B; Kornblau S; Giles F J; Koller C; Gajewski J; Talpaz M
Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
Leukemia & lymphoma 1999;35(5-6):483-9.
1999: Thomas D A; Kantarjian H; Smith T L; Koller C; Cortes J; O'Brien S; Giles F J; Gajewski J; Pierce S; Keating M J
Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy.
Cancer 1999;86(7):1216-30.
1999: Aguayo A; Cortes J; Thomas D; Pierce S; Keating M; Kantarjian H
Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia.
Cancer 1999;86(7):1203-9.
1999: Estey E H; Giles F J; Kantarjian H; O'Brien S; Cortes J; Freireich E J; Lopez-Berestein G; Keating M
Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia.
Blood 1999;94(7):2230-5.
1999: Faderl S; Estrov Z; Kantarjian H M; Thomas D; Cortes J; Manshouri T; Chan C C; Hays K J; Pierce S; Albitar M
The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia.
Cytokines, cellular & molecular therapy 1999;5(3):159-63.
1999: Beran M; Estey E; O'Brien S; Cortes J; Koller C A; Giles F J; Kornblau S; Andreeff M; Vey N; Pierce S R; Hayes K; Wong G C; Keating M; Kantarjian H
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2819-30.
1999: Ravandi-Kashani F; Cortes J; Cohen P; Talpaz M; O'Brien S; Markowitz A; Kantarjian H
Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders.
Leukemia & lymphoma 1999;35(1-2):109-18.
1999: Cortes J; Fayad L; O'Brien S; Keating M; Kantarjian H
Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2491-7.
1999: Giles F J; Kantarjian H M; Cortes J; Thomas D A; Talpaz M; Manshouri T; Albitar M
Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance.
Cancer 1999;86(5):805-13.
1999: Thomas D A; Cortes J; O'Brien S; Pierce S; Faderl S; Albitar M; Hagemeister F B; Cabanillas F F; Murphy S; Keating M J; Kantarjian H
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2461-70.
1999: Faderl S; Kantarjian H M; Manshouri T; Chan C Y; Pierce S; Hays K J; Cortes J; Thomas D; Estrov Z; Albitar M
The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1855-61.
1999: Ravandi-Kashani F; Estey E; Cortes J; Medeiros L J; Giles F J
Granulocytic sarcoma of the pancreas: a report of two cases and literature review.
Clinical and laboratory haematology 1999;21(3):219-24.
1999: Ravandi-Kashani F; Cortes J; Talpaz M; Kantarjian H M
Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect?
Cancer 1999;85(12):2583-8.
1999: Dabaja B S; Faderl S; Thomas D; Cortes J; O'Brien S; Nasr F; Pierce S; Hayes K; Glassman A; Keating M; Kantarjian H M
Deletions and losses in chromosomes 5 or 7 in adult acute lymphocytic leukemia: incidence, associations and implications.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1999;13(6):869-72.
1999: Vey N; Kantarjian H; Tran H; Beran M; O'Brien S; Bivins C; Giles F; Cortes J; Cheson B; Arbuck S; Estey E
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(5):577-83.
1999: Estey E H; Thall P F; Pierce S; Cortes J; Beran M; Kantarjian H; Keating M J; Andreeff M; Freireich E
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Blood 1999;93(8):2478-84.
1999: Kantarjian H M; O'Brien S; Smith T L; Rios M B; Cortes J; Beran M; Koller C; Giles F J; Andreeff M; Kornblau S; Giralt S; Keating M J; Talpaz M
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):284-92.
1999: Vey N; Kantarjian H; Beran M; O'Brien S; Cortes J; Koller C; Estey E
Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study.
Investigational new drugs 1999;17(1):89-95.
1999: Cortes J; O'Brien S; Estey E; Giles F; Keating M; Kantarjian H
Phase I study of liposomal daunorubicin in patients with acute leukemia.
Investigational new drugs 1999;17(1):81-7.
1998: Rodriguez J; Cortes J; Smith T; O'Brien S; Rios M B; Talpaz M; Kantarjian H
Determinants of prognosis in late chronic-phase chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(12):3782-7.
1998: Cortes J; Talpaz M; O'Brien S; Rios M B; Majlis A; Keating M; Freireich E J; Kantarjian H
Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3279-85.
1998: Cortes J; Fayad L; Kantarjian H; O'Brien S; Lee M S; Talpaz M
Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(4):455-62.
1997: Bseiso A W; Kantarjian H M; Guo J Q; Cortes J; Talpaz M; Koller C; AlBitar M; Keating M; Arlinghaus R
Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(9):1583-7.
1997: Cortes J; Kurzrock R
Interleukin-10 in non-Hodgkin's lymphoma.
Leukemia & lymphoma 1997;26(3-4):251-9.
1997: Sacchi S; Cortes J; Kantarjian H; Talpaz M
Effects of interferon-alpha therapy on lymphocyte subpopulations in patients with chronic myeloid leukemia.
Hematopathology and molecular hematology 1997;11(1):41-7.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Jorge Cortes

Research Profile (preview)

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Jorge Cortes (preview)

All Publications